



UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Subhashis Banerjee et al.
Serial No. : 10/622,210
Filed : July 18, 2003
Entitled : TREATMENT OF
 VASCULITIDES USING
 TNFALPHA INHIBITORS

ART UNIT: 1643

EXAMINER: Blanchard, Daivd J.

Attorney Docket No. BBC-207

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

The undersigned hereby certifies that this correspondence is being deposited with the U.S. Postal Service as First Class Mail, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

August 29, 2006
date of mailing and signature

Lisa Rasmussen

TRANSMITTAL LETTER

Sir/Madam:

Transmitted herewith are: Change of Attorney Docket Number and Change of Correspondence Address; An Information Disclosure Statement under 37 CFR §§ 1.56, 1.97 and 1.98; Form PTO-1449 Information Disclosure Statement; A photocopy of each reference cited; and An Acknowledgement Postcard; to be filed in the above-identified patent application.

FEE FOR ADDITIONAL CLAIMS

- A fee for additional claims is not required.
 A fee for additional claims is required. The additional fee has been calculated as shown below:


	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXCESS CLAIMS	RATE	FEES DUE
TOTAL CLAIMS		29	0	× \$50	= 0.00
INDEPENDENT		11	0	× \$200	= 0.00
FIRST INTRODUCTION OF MULT. DEPENDENT CLAIM			+ \$360	=	0.00
TOTAL FEES DUE					= 00.00

PETITION FOR EXTENSION OF TIME

[] Extension is requested under 37 CFR 1.136(a), and the following extension fee is applicable for the paper(s) filed herewith: [] \$120.00 for response within first month pursuant to 37 CFR 1.17(a)(1);
[] \$450.00 for response within second month pursuant to 37 CFR 1.17(a)(2);
[] \$1020.00 for response within third month pursuant to 37 CFR 1.17(a)(3);
[] \$1,590.00 for response within fourth month pursuant to 37 CFR 1.17(a)(4).
[] \$2,160.00 for response within fifth month pursuant to 37 CFR 1.17(a)(5).

[X] The Commissioner is hereby authorized to charge payment of any additional fees required in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to **Deposit Account No. 010025**. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,



Tara Seshadri, Ph.D.
Agent for Applicant
Registration No. 48,591
Abbott Bioresearch Center
100 Research Drive
Worcester, MA 01605-4314
Telephone: (508) 688-8058
Telefax: (508) 688-8110



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Subhashis Banerjee et al.

Serial No.: 10/622,210

ART UNIT: 1643

Filed: July 18, 2003

EXAMINER: Blanchard, Daivd J.

Entitled: : TREATMENT OF
VASCULITIDES USING
TNFALPHA INHIBITORS

Attorney Docket No.: BBC-207

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

The undersigned hereby certifies that this correspondence is being deposited with the U.S. Postal Service as First Class Mail, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

August 29, 2006

Date


Lisa Rasmussen

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Sir/Madam:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 for the above-identified application. Applicants makes the following publications of record in the above-identified application.

U.S. Patent Documents

Le et al., August 12, 1997, U.S. Patent No. 5,656,272

Foreign Patent Documents

Shenoy et al., September 19, 2002, WO 02/072636

Other Publications

- Barron *et al.*, *J. Rheumatology*, (1999); 26(1): 170-190.
Blank *et al.*, *Clin. Exp. Immunol.*, (1995); 102: 120-130.
Brahn *et al.*, *Clin. Immunol.*, (1999); 90(1): 147-151.
Brouwer *et al.*, *J. Exp. Med.*, (1993); 177: 905-914.
Churg, A., *Mod. Pathol.*, (2001); 14(12): 1284-1293.
Cotch, M.F., *Curr. Opin. Rheumatol.*, (2000); 12: 20-23.
Damianovich *et al.*, *J. Immunol.*, (1996); 156: 4946-4951.
Deguchi *et al.*, *Clin. Exp. Immunol.*, (1990); 81: 311-314.
Deguchi *et al.*, *Lancet*, (1989); 2: 745-746.
DiGirolamo *et al.*, *J. of Leukocyte Biology*, (1997); 61: 667-678.
Dogan *et al.*, *Oftamologia*, (2002); 51: 23-30.
Duong *et al.*, *Int. Immunol.*, (2002); 15(1): 79-89.
Fraga *et al.*, *Curr. Rheumatol. Rep.*, (2002); 4: 30-38.
Francis, G.E., *Focus on Growth Factors*. (1992); 3: 4-10.
Gedalia, A., *Curr. Rheumatol. Rep.*, (2002); 4: 25-29.
Gross, W.L., *Curr. Opin. Rheumatol.*, (2002); 14: 11-14.
Grunebaum *et al.*, *Clin. Exp. Immunol.*, (2002); 130: 233-240.
Harman *et al.*, *Survey of Ophthalmology*, (1998); 42(5): 458-480.
Hirata *et al.*, *Acta. Otolaryngol. Suppl.*, (1993); 503: 79-81.
Hoffman *et al.*, *Arthritis & Rheum.*, (1998); 41(12): 2257-2262.
Kaklamani *et al.*, *Semin. Arthritis Rheum.*, (2001); 30(5): 299-312.
Keffer *et al.*, *EMBO J.*, (1991); 10(13): 4025-4031.
Kinjoh *et al.*, *Proc. Natl. Acad. Sci. USA*, (1993); 90: 3413-3417.
Kobayashi *et al.*, *Intern. Med.* (2002); 41(1): 44-46.
Lehman *et al.*, *Arthritis & Rheum.* (1985); 28(6): 652-659.
Marquez *et al.*, *Curr. Rheumatol. Rep.* (2003); 5: 128-135.
Marzi *et al.*, *Shock*, (1995); 3(1): 27-33.
Nose *et al.*, *Am. J. Path.*, (1996); 149(5): 1763-1769.
Old, L., *Science*, (1985); 230: 630-632.
Schett *et al.*, *Ann. Rheum. Dis.*, (2002); 61: 463-467.
Sfikakis *et al.*, *Ann. Rheum. Dis.*, (2002); 61: ii51-ii53.
Silman *et al.*, *Lancet*, (1990); 335: 1078-1080.
Sneller, M.C., *Cleve. Clin. J. Med.*, (2002); 69: SII40- SII43.
Straub *et al.*, *Rheumatology(Oxford)*, (2002); 41: 423-429.
Sundel, R.P., *Curr. Rheumatol. Rep.*, (2002); 4: 474-482.
Tomer *et al.*, *Arthritis & Rheum.* (1995); 38(10): 1375-1381.
Uddhammar *et al.*, *Brit. J. Rheumatol.*, (1998); 37: 766-769.
Williams *et al.*, *Proc. Natl. Acadd.Sci. USA.*, (1992); 89: 9784-9788.


Form PTO-1449 listing each of these documents and photocopies of each document are enclosed herewith for the Examiner's convenience.

This paper is being mailed before the mailing of a first Office action. Pursuant to 37 CFR §1.97(b)(4), no fee is required with this submission.

Applicant does not intend to represent that any of the documents submitted herein is material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Respectfully submitted,



Tara Seshadri, Ph.D.
Agent for Applicant
Registration No. 48,591
Abbott Bioresearch Center
100 Research Drive
Worcester, MA 01605-4314
Telephone: (508) 688-8058
Telefax: (508) 688-8110

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

SEP 01 2006

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1 of 5

Complete if Known

Application Number	10/622,210
Filing Date	July 18, 2003
First Named Inventor	Subhashis Banerjee
Art Unit	1643
Examiner Name	David J. Blanchard

Attorney Docket Number BBC-207

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **¹** Applicant's unique citation designation number (optional). **²** See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. **³** Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). **⁴** For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **⁵** Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. **⁶** Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/622,210
Sheet	2	of	5	Filing Date	July 18, 2003
				First Named Inventor	Subhashis Banerjee
				Art Unit	1643
				Examiner Name	David J. Blanchard
				Attorney Docket Number	BBC-207

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	3	Barron et al., "Report of the National Institutes of Health Workshop on Kawasaki Disease", <i>J. Rheumatology</i> , (1999); 26(1): 170-190.		
	4	Blank et al., "Immunization with anti-neutrophil cytoplasmic antibody (ANCA) induces the production of mouse ANCA and perivascular lymphocyte infiltration", <i>Clin. Exp. Immunol.</i> , (1995); 102: 120-130.		
	5	Brahn et al., "Suppression of coronary vasculitis in a murine model of Kawasaki Disease using an angiogenesis inhibitor", <i>Clin. Immunol.</i> , (1999); 90(1): 147-151.		
	6	Brouwer et al., "Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model", <i>J. Exp. Med.</i> , (1993); 177: 905-914.		
	7	Churg, A., "Recent advances in the diagnosis of Churg-Strauss Syndrome", <i>Mod. Pathol.</i> , (2001); 14(12): 1284-1293.		
	8	Cotch, M.F., "The socioeconomic impact of vasculitis", <i>Curr. Opin. Rheumatol.</i> , (2000); 12: 20-23.		
	9	Damianovich et al., "Pathogenic role of anti-endothelial cell antibodies in vasculitis", <i>J. Immunol.</i> , (1996); 156: 4946-4951.		
	10	Deguchi et al., "Enhanced expression of the tumour necrosis facto/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis", <i>Clin. Exp. Immunol.</i> , (1990); 81: 311-314.		
	11	Deguchi et al., "Enhanced transcription of TNF in systemic vasculitis", <i>Lancet</i> , (1989); 2: 745-746.		
	12	DiGirolamo et al., "Expression of TNF-a by human plasma cells in chronic inflammation", <i>J. of Leukocyte Biology</i> , (1997); 61: 667-678.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/622,210
				Filing Date	July 18, 2003
				First Named Inventor	Subhashis Banerjee
				Art Unit	1643
				Examiner Name	David J. Blanchard
Sheet	3	of	5	Attorney Docket Number	BBC-207

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	13	Dogan et al., "Sindromul Behcet", Oftalmologia, (2002); 52: 23-30.		
	14	Duong et al., "Superantigenic activity is responsible for induction of coronary arteritis in mice: an animal model of Kawasaki disease", Int. Immunol., (2002); 15(1); 79-89.		
	15	Fraga et al., "Takayasu's Artheritis", Curr. Rheumatol. Rep., (2002); 4: 30-38.		
	16	Francis, G.E., "Protein modification and fusion proteins", Focus on Growth Factors. (1992); 3: 4-10		
	17	Gedalia, A., "Kawasaki Disease: an update", Curr. Rheumatol. Rep., (2002); 4: 25-29.		
	18	Gross, W.L., "Churg-Strauss syndrome: update on recent developments", Curr. Opin. Rheumatol., (2002); 14: 11-14.		
	19	Grunebaum et al., "The role of anti-endothelial cell antibodies in Kawasaki disease – in vitro and in vivo studies", Clin. Exp. Immunol., (2002); 130: 233-240.		
	20	Harman et al., "Experimental Vestibular Neuritis Induced by Herpes Simplex Virus", Survey of Ophthalmology, (1998); 42(5): 458-480.		
	21	Hirata et al., "Wegener's Granulomatosis", Acta. Otolaryngol. Suppl., (1993); 503: 79-81.		
	22	Hoffman et al., "Wegener's Granulomatosis", Arthritis & Rheum., (1998); 41(12): 2257-2262.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

5

Application Number	10/622,210
Filing Date	July 18, 2003
First Named Inventor	Subhashis Banerjee
Art Unit	1643
Examiner Name	David J. Blanchard

Attorney Docket Number BBC-207

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	23	Kaklamani et al., "Treatment of Behcet's Disease – an update", Semin. Arthritis Rheum., (2001); 30(5): 299-312.	
	24	Keffer et al., "Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis", EMBO J., (1991); 10(13): 4025-4031.	
	25	Kinjoh et al., "Genetic selection for crescent formation yields mouse strain with rapidly progressive glomerulonephritis and small vessel vasculitis", Proc. Natl. Acad. Sci. USA, (1993); 90: 3413-3417.	
	26	Kobayashi et al., "TakayasuArteritis", Intern. Med. (2002); 41(1): 44-46.	
	27	Lehman et al., "Coronary arteritis in mice following the systemic injection of group B lactobacillus casei cell walls in aqueous suspension", Arthritis & Rheum. (1985); 28(6): 652-659.	
	28	Marquez et al., "Granulomatous vasculitis", Curr. Rheumatol. Rep. (2003); 5: 128-135.	
	29	Marzi et al., "Effect of anti-tumor necrosis factor α on leukocyte adhesion in the liver after hemorrhagic shock: an intravital microscopic study in the rat", Shock, (1995); 3(1): 27-33.	
	30	Nose et al., "Arteritis in a novel congenic strain of mice derived from MRL/lpr lupus mice", Am. J. Path., (1996); 149(5): 1763-1769.	
	31	Old, L., "Tumor Necrosis Factor (TNF)", Science, (1985); 230: 630-632.	
	32	Schett et al., Obstruction of the pulmonary artery by granulomatous vasculitis: a clinical, morphological, and immunological analysis", Ann. Rheum. Dis., (2002); 61: 463-467.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

*Complete if Known***INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

5

of

5

Application Number	10/622,210
Filing Date	July 18, 2003
First Named Inventor	Subhashis Banerjee
Art Unit	1643
Examiner Name	David J. Blanchard

Attorney Docket Number

BBC-207

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	33	Sfikakis et al., "Behcet's disease: a new target for anti-tumour necrosis factor treatment", Ann. Rheum. Dis., (2002); 61: ii51-ii53.	
	34	Silman et al., "Criteria for diagnosing Behcet's disease", Lancet, (1990); 335: 1078-1080.	
	35	Sneller, M.C., "Granuloma formation, implications for the pathogenesis of vasculitis", Cleve. Clin. J. Med., (2002); 69: SII40- SII43.	
	36	Straub et al., "In polymyalgia rheumatica serum prolactin is positively correlated with the number of typical symptoms but not with typical inflammatory markers", <i>Rheumatology (Oxford)</i> , (2002); 41: 423-429.	
	37	Sundel, R.P., "Update on the treatment of Kawasaki disease in childhood", Curr. Rheumatol. Rep., (2002); 4: 474-482.	
	38	Tomer et al., "Characterization of biologically active antineutrophil cytoplasmic antibodies induced in mice", Arthritis & Rheum. (1995); 38(10): 1375-1381.	
	39	Uddhammar et al., "Cytokines and adhesion molecules in patients with polymyalgia rheumatica", Brit. J. Rheumatol., (1998); 37: 766-769.	
	40	Williams et al., "Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis", Proc. Natl. Acad. Sci. USA., (1992); 89: 9784-9788.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.